Results 1 to 10 of about 218,137 (295)
Chronic Diseases and Translational Medicine, 2019 After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy.
Wei-Bo Yu, Jian-Yu Rao
doaj +3 more sources
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade [PDF]
Immunity, Inflammation and Disease, 2021 Introduction Chronic infections lead to the functional exhaustion of T cells. Exhausted T cells are phenotypically differentiated by the surface expression of the immunoinhibitory receptor, such as programmed death‐1 (PD‐1).
Otgontuya Ganbaatar +13 more
doaj +4 more sources
Zhongliu Fangzhi Yanjiu, 2022 Objective To investigate the expression of PD-1 and PD-L1/2 in T cell subsets and myeloma cells in the bone marrow from newly diagnosed multiple myeloma (NDMM) patients and their relation with clinical features.
MA Yinjuan +8 more
doaj +1 more source
GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression [PDF]
Journal of Pathology and Translational Medicine, 2017 Background Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or ...
Young Wha Koh +5 more
doaj +1 more source
Assessment of PD-L1 expression in patients with neuroblastoma and renal tumors
The Turkish Journal of Pediatrics, 2021 Background. Programmed death 1 (PD-1) is a co-receptor which is located at the surface of cells like natural killer, monocytes, T and B cells. It has two ligands including programmed death ligand-1 (PD-L1) and ligand-2 (PD-L2).
Seher Şener +4 more
doaj +1 more source
Emerging role of the immunotherapy in treatment of breast cancer
SVU - International Journal of Medical Sciences, 2021 Background: Breast cancer is a life-threatening malignant tumor that ranks the most frequent cancerin females worldwide. Emerging studies suggest the important role of the immunotherapy in breast cancer.Triple negative breast cancer (TNBC) is associated ...
Nagwa Abd El-Sadek Ahmed* +1 more
doaj +1 more source
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors [PDF]
, 2016 PURPOSE: Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune response through inhibition of T-cell checkpoints has led to durable clinical responses ...
Agar, Nathalie Y. R. +13 more
core +21 more sources
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients [PDF]
Journal of Pathology and Translational Medicine, 2017 Background Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells.
Jiheun Han, Yongkil Hong, Youn Soo Lee
doaj +1 more source
Indian Journal of Rheumatology, 2022 Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases.
Eman Eissa +6 more
doaj +1 more source
Diagnostics, 2021 Periampullary cancers (PACs) are characterized by tumor-infiltrating lymphocytes (TILs), severe fibrosis, and epithelial to mesenchymal transition (EMT).
Nishant Thakur +3 more
doaj +1 more source